Zenas Biopharma Inc (ZBIO)

$26.03 -0.04 (-0.15%)
Market Cap 1.40B
Revenue (ttm) 5.00M
Net Income (ttm) -156.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,139.80%
Debt to Equity Ratio 0.00
Volume 2,847,900
Avg Vol 949,234
Day's Range N/A - N/A
Shares Out 53.68M
Stochastic %K 46%
Beta -1.50
Analysts Strong Sell
Price Target $40.75

Company Profile

Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal anti...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 271 2954
Address:
852 Winter Street, Suite 250, Waltham, United States
AIIAAIIA_88
AIIAAIIA_88 Feb. 25 at 9:12 PM
$ZBIO Someone dumped?? Why?
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Feb. 25 at 8:52 PM
$ZBIO Oh, what was that?
0 · Reply
kubota2323
kubota2323 Feb. 25 at 3:55 PM
$CLYM $CGEM $ZBIO $NVS $SNY giddy up
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Feb. 24 at 3:13 PM
$ZBIO Getting ready to POP in a major way soon. JMO
0 · Reply
UgoGreg
UgoGreg Feb. 21 at 4:06 PM
$ZBIO https://youtu.be/ygBN8MilTyc
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Feb. 20 at 12:34 AM
$ZBIO This one has effectively proven its efficacy for the compound for autoimmune diseases, although the specific targeted disease fell “short” of Amgen’s existing drug. But, there could be and shall be many other applicable indications! The compound has outstanding safety profile. Would not be surprised if bigger firms such as GILD or ABBV make offer to buyout! JMO
1 · Reply
staydowngetdown
staydowngetdown Feb. 18 at 7:59 PM
$ZBIO 💎
0 · Reply
nopennys
nopennys Feb. 18 at 1:56 PM
$ZBIO $MLTX $OCUL All three have something common! They made it crash citing as over reaction and loaded up at the bottom See the chart of all three! Bought the dips and chillaxing! Abrakadabra 🚀
0 · Reply
notreload_ai
notreload_ai Feb. 18 at 1:40 PM
Wall Street analysts are bullish on $ZBIO and $BIOA with strong upgrades, highlighting near-term FDA potential and promising drug data for big growth in 2026. https://notreload.xyz/zenas-biopharma-bioage-labs-hot-biotech-upgrades-to-watch/
0 · Reply
mahaljs
mahaljs Feb. 17 at 10:04 PM
$ZBIO - Back to $44 again soon
0 · Reply
Latest News on ZBIO
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 20, 2026, 4:15 PM EST - 5 days ago

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026

Feb 9, 2026, 7:05 AM EST - 17 days ago

Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026

Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 7:05 AM EST - 22 days ago

Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

These 20 stocks are strong choices for momentum investors

Jan 22, 2026, 10:26 AM EST - 4 weeks ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 16, 2026, 4:15 PM EST - 5 weeks ago

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease Transcript

Jan 6, 2026, 2:58 PM EST - 7 weeks ago

Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease Transcript

Why Zenas BioPharma's Selloff Was Structurally Inevitable

Jan 6, 2026, 7:38 AM EST - 7 weeks ago

Why Zenas BioPharma's Selloff Was Structurally Inevitable

Zenas: Maintaining 'Strong Buy' As Cross-Trial Comparison Of Obexelimab Should Not Be A Factor

Jan 6, 2026, 4:58 AM EST - 7 weeks ago

Zenas: Maintaining 'Strong Buy' As Cross-Trial Comparison Of Obexelimab Should Not Be A Factor

Zenas BioPharma Touts Phase 3 Win, But Stock Crashes

Jan 5, 2026, 10:21 AM EST - 7 weeks ago

Zenas BioPharma Touts Phase 3 Win, But Stock Crashes

Zenas BioPharma's immune disorder drug meets main goal in late-stage trial

Jan 5, 2026, 8:29 AM EST - 7 weeks ago

Zenas BioPharma's immune disorder drug meets main goal in late-stage trial

Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

Jan 5, 2026, 7:05 AM EST - 7 weeks ago

Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus

Dec 15, 2025, 7:05 AM EST - 2 months ago

Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus

Zenas Prepares For INDIGO Phase 3 Readout - Reinstating Buy Rating

Dec 15, 2025, 4:18 AM EST - 2 months ago

Zenas Prepares For INDIGO Phase 3 Readout - Reinstating Buy Rating

Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 7:05 AM EST - 3 months ago

Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

Nov 11, 2025, 7:05 AM EST - 3 months ago

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis

Oct 27, 2025, 7:05 AM EDT - 4 months ago

Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis

Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal

Oct 9, 2025, 8:00 AM EDT - 5 months ago

Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal

Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug

Oct 8, 2025, 6:04 AM EDT - 5 months ago

Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug

Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis

Oct 8, 2025, 5:00 AM EDT - 5 months ago

Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

Sep 2, 2025, 7:05 AM EDT - 6 months ago

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

RPRX

Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Aug 12, 2025, 7:05 AM EDT - 7 months ago

Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS

Jul 28, 2025, 1:42 PM EDT - 7 months ago

Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS

FINAL ALERT NOTICE - ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO

Jun 16, 2025, 3:44 AM EDT - 9 months ago

FINAL ALERT NOTICE - ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

Jun 15, 2025, 10:44 AM EDT - 9 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

Jun 12, 2025, 6:17 PM EDT - 9 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO

Jun 11, 2025, 10:24 AM EDT - 9 months ago

ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

May 31, 2025, 8:55 AM EDT - 9 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

AIIAAIIA_88
AIIAAIIA_88 Feb. 25 at 9:12 PM
$ZBIO Someone dumped?? Why?
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Feb. 25 at 8:52 PM
$ZBIO Oh, what was that?
0 · Reply
kubota2323
kubota2323 Feb. 25 at 3:55 PM
$CLYM $CGEM $ZBIO $NVS $SNY giddy up
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Feb. 24 at 3:13 PM
$ZBIO Getting ready to POP in a major way soon. JMO
0 · Reply
UgoGreg
UgoGreg Feb. 21 at 4:06 PM
$ZBIO https://youtu.be/ygBN8MilTyc
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Feb. 20 at 12:34 AM
$ZBIO This one has effectively proven its efficacy for the compound for autoimmune diseases, although the specific targeted disease fell “short” of Amgen’s existing drug. But, there could be and shall be many other applicable indications! The compound has outstanding safety profile. Would not be surprised if bigger firms such as GILD or ABBV make offer to buyout! JMO
1 · Reply
staydowngetdown
staydowngetdown Feb. 18 at 7:59 PM
$ZBIO 💎
0 · Reply
nopennys
nopennys Feb. 18 at 1:56 PM
$ZBIO $MLTX $OCUL All three have something common! They made it crash citing as over reaction and loaded up at the bottom See the chart of all three! Bought the dips and chillaxing! Abrakadabra 🚀
0 · Reply
notreload_ai
notreload_ai Feb. 18 at 1:40 PM
Wall Street analysts are bullish on $ZBIO and $BIOA with strong upgrades, highlighting near-term FDA potential and promising drug data for big growth in 2026. https://notreload.xyz/zenas-biopharma-bioage-labs-hot-biotech-upgrades-to-watch/
0 · Reply
mahaljs
mahaljs Feb. 17 at 10:04 PM
$ZBIO - Back to $44 again soon
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 17 at 7:00 PM
$ZBIO RSI: 72.74, MACD: -0.0410 Vol: 2.54, MA20: 21.47, MA50: 27.66 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
_OnyxPredator
_OnyxPredator Feb. 17 at 6:31 PM
$WOLF $HOTH $SNES $ZBIO 3•
0 · Reply
smalltraderjoe
smalltraderjoe Feb. 17 at 4:33 PM
$ZBIO manipulation started, the spread between the ask and the bid price is now 85 cents per IBKR
0 · Reply
smalltraderjoe
smalltraderjoe Feb. 17 at 4:23 PM
$ZBIO short shares are being borrowed and only 97K available on IBKR . So is it a part market manipulation to inflate the price and then short it down to the ground?
0 · Reply
OnyxPredator
OnyxPredator Feb. 17 at 4:15 PM
$VTVT $ZBIO $PGEN $SQFT ””””
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Feb. 17 at 2:25 PM
$ZBIO I thought something was cooking last Thursday!
0 · Reply
StardustTrader
StardustTrader Feb. 16 at 7:24 PM
$ZBIO averaged in at 20. With may and december calls on top.
1 · Reply
UgoGreg
UgoGreg Feb. 15 at 5:51 PM
$ZBIO https://youtu.be/nCPt9XhiRxk
0 · Reply
TwoToesTrading
TwoToesTrading Feb. 14 at 2:55 PM
$OVBC $RBBN $ZBIO $CLF $NDAQ some insider buying and some 10b5-1s
0 · Reply
FilingTracker
FilingTracker Feb. 13 at 10:08 PM
$ZBIO Insider purchased ~$500K worth of shares at $25.16/share: https://www.sec.gov/Archives/edgar/data/1348587/000110465926015342/xslF345X05/tm266411-1_4seq1.xml
0 · Reply
nikserr
nikserr Feb. 13 at 8:16 PM
$UPB The same story as $ZBIO. Bought $10-11 sold at $22. Easy Pizzy !!
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Feb. 13 at 5:11 PM
$ZBIO What was the catalyst for yesterday's run? Just an ANALyst upgrade?
0 · Reply